{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T17:13:13Z","timestamp":1791133993703,"version":"4.1.0"},"reference-count":26,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Clinical Trials"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1310\/hct1405-192","type":"journal-article","created":{"date-parts":[[2013,10,21]],"date-time":"2013-10-21T21:51:21Z","timestamp":1382392281000},"page":"192-203","source":"Crossref","is-referenced-by-count":107,"title":["Pharmacokinetics, Safety, and Monotherapy Antiviral Activity of GSK1265744, an HIV Integrase Strand Transfer Inhibitor"],"prefix":"10.1080","volume":"14","author":[{"given":"W.","family":"Spreen","sequence":"first","affiliation":[{"name":"GlaxoSmithKlineResearch Triangle Park, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Min","sequence":"additional","affiliation":[{"name":"GlaxoSmithKlineResearch Triangle Park, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. L.","family":"Ford","sequence":"additional","affiliation":[{"name":"GlaxoSmithKlineResearch Triangle Park, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Chen","sequence":"additional","affiliation":[{"name":"GlaxoSmithKlineResearch Triangle Park, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Lou","sequence":"additional","affiliation":[{"name":"GlaxoSmithKlineResearch Triangle Park, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bomar","sequence":"additional","affiliation":[{"name":"GlaxoSmithKlineResearch Triangle Park, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"St Clair","sequence":"additional","affiliation":[{"name":"GlaxoSmithKlineResearch Triangle Park, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Piscitelli","sequence":"additional","affiliation":[{"name":"GlaxoSmithKlineResearch Triangle Park, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Fujiwara","sequence":"additional","affiliation":[{"name":"Shionogi & Co., Ltd, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2014,12,22]]},"reference":[{"key":"e_1_2_1_2_1","first-page":"25","article-title":"Raltegravir, elvitegravir, and metoogravir: The birth of \u201cme-too\u201d HIV-1 integrase inhibitors.","volume":"6","author":"Serrao E","year":"2009","unstructured":"Serrao E, Odde S, Ramkumar K, Neamati N. Raltegravir, elvitegravir, and metoogravir: The birth of \u201cme-too\u201d HIV-1 integrase inhibitors. Retro virology. 2009;6:25.","journal-title":"Retro virology"},{"key":"e_1_2_1_3_1","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adoles-cents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. http:\/\/aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf. Section accessed October 18 2012 [F-4 Table 5a]."},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708978"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S7775"},{"key":"e_1_2_1_6_1","unstructured":"DeJesus E Cohen C Elion R et al. First report of raltegra-vir (RAL MK-0518) use after virologic rebound on elvite-gravir (EVT GS 9137). Presented at: 4th IAS Conference on HIV Pathogenesis Treatment and Prevention; July 22\u201325 2007; Sydney Australia. Abstract TUPEB032."},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm301550c"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31826bfd02"},{"key":"e_1_2_1_9_1","unstructured":"Min S DeJesus E McCurdy L et al. Pharmacokinetics (pK) and safety in healthy and HIV-infected subjects and short-term antiviral efficacy of S\/G5K1265744 a next generation once daily HIV integrase inhibitor [poster]. Pre-sented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12\u201315 2009; San Francisco CA."},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01209-10"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028238"},{"key":"e_1_2_1_12_1","unstructured":"Yoshinaga T Kobayashi M Seki T et al. Antiviral charac-teristics of S\/G5K1265744 an HIV integrase inhibitor (INI) dosed by oral or long-acting parenteral injection [slides]. Presented at: 52nd ICAAC Interscience Conference on Antimicrobial Agents and Chemotherapy; September 9\u201312 2012; San Francisco CA."},{"key":"e_1_2_1_13_1","unstructured":"National Institutes of Allergy and Infectious Diseases Divi-sion of Acquired Immunodeficiency Syndrome. Division of AIDS table for grading the severity of adult and pediatric adverse events. http:\/\/rsc.tech-res.com\/Document\/safe-tyandpharmacovigilance\/Table_for_Grading_Severity_of_Adult_Pediatric_Adverse_Events.pdf. Accessed April 6 2012."},{"key":"e_1_2_1_14_1","first-page":"S10","article-title":"for the P005 Study Team. Resistance to the HIV-integrase inhibitor raltegravir: analysis of protocol 005, a Phase ll study in patients with triple-class resistant HIV-1 infection [abstract 8]","volume":"12","author":"Hazuda DJ","year":"2007","unstructured":"Hazuda DJ, Miller MD, Nguyen BY, Zhao J, for the P005 Study Team. Resistance to the HIV-integrase inhibitor raltegravir: analysis of protocol 005, a Phase ll study in patients with triple-class resistant HIV-1 infection [abstract 8]. Antivir Ther. 2007;12:S10.","journal-title":"Antivir Ther"},{"key":"e_1_2_1_15_1","first-page":"S11","article-title":"Resistance and cross-resistance to first generation integrase inhibitors: Insights from a Phase ll study of elvitegravir (GS-9137) [abstract 9].","volume":"12","author":"McColl DJ","year":"2007","unstructured":"McColl DJ, Fransen S, Gupta S, et al. Resistance and cross-resistance to first generation integrase inhibitors: Insights from a Phase ll study of elvitegravir (GS-9137) [abstract 9]. Antivir Ther. 2007;12:S11.","journal-title":"Antivir Ther"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr152"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00842-09"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32834a1dd9"},{"key":"e_1_2_1_19_1","first-page":"35","article-title":"Safety, efficacy, and pharmacokinetics of rilpivirine: Systematic review with an emphasis on resource-limited settings","volume":"3","author":"Ford N","year":"2011","unstructured":"Ford N, Lee J, Andrieux-Meyer I, Calmy A. Safety, efficacy, and pharmacokinetics of rilpivirine: Systematic review with an emphasis on resource-limited settings. HIV\/AIDS (Auckl). 2011;3:35\u201344.","journal-title":"HIV\/AIDS (Auckl)"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425250903483207"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199856060-00016"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000233308.82860.2f"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200311210-00011"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/3293"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200101050-00002"},{"key":"e_1_2_1_26_1","unstructured":"Pozniak AL F\u00e4tkenheuer G Johnson M et al. Effect of short-term monotherapy with UK-427 857 on viral load in HIV-infected patients [slides]. Presented at: 43rd Inter- science Conference on Antimicrobial Agents and Chemo-therapy; September 14\u201317 2003; Chicago IL."},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32832fef5b"}],"container-title":["HIV Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1310\/hct1405-192","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T21:51:51Z","timestamp":1770414711000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1310\/hct1405-192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["10.1310\/hct1405-192"],"URL":"https:\/\/doi.org\/10.1310\/hct1405-192","relation":{},"ISSN":["1528-4336","1945-5771"],"issn-type":[{"value":"1528-4336","type":"print"},{"value":"1945-5771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10]]}}}